What We Are Watching
Neurotechnology · Healthcare · Defense
The Non-Invasive BCI Platform Is Being Built Faster Than the Market Realizes — and China Is Leading It
BrainCo raised $280 million — second only to Neuralink — as a non-invasive EEG company. The wearable brain device market is growing at 23% CAGR. The data layer being built from millions of neural data points is the strategic asset most corporate analysts are not tracking.
6/10/2026
What We Are Watching is Vaxa's signal intelligence column. We identify markets, technologies, and structural shifts already in motion but may not yet reached the corporate strategy conversation.
highlights
01
BrainCo raised roughly $280 million — second only to Neuralink in BCI funding — as a non-invasive EEG company, not an implant company
02
The wearable brain device market is projected to grow from $574 million in 2025 to $2.5 billion by 2032 at a 23% CAGR
03
Non-invasive BCI is moving from niche consumer wellness to a platform at the intersection of rehabilitation, performance, and cognitive data collection
04
The dual-use dimension — civilian neurotechnology funded by military-linked capital — is the strategic subtext most corporate analysis misses
05
The companies positioned to capture value are not necessarily the device makers — the data layer is where the durable strategic asset is forming
Signal
BrainCo's recent $280 million raise pulled the Hangzhou-based company into the same funding tier as Neuralink. That comparison is striking not because BrainCo is building implants. It is striking precisely because it is not.
The prevailing assumption in the BCI field is that the serious money and the serious capability are on the invasive side. BrainCo's capital position challenges that assumption. A non-invasive EEG company, built around wearable headbands, rehabilitation hardware, and education-adjacent training tools, is now operating at a scale previously reserved for clinical neural interface platforms.
The assumption that the real BCI money is on the invasive side just took a $280 million exception.
Pattern
Non-invasive brain-computer interface refers to systems that measure brain activity externally — typically through EEG sensors worn on the head — rather than through implanted electrodes. The signal quality is fundamentally lower than invasive approaches. The limitation is real. It is also less constraining than it sounds for most commercial applications.
BrainCo's prosthetic hand received FDA clearance in 2022 as a Class II medical device. It uses brain waves and muscle signals to intuit movement. The clinical validation is real.
The non-invasive pathway will not produce what Neuralink is building. It will produce something different — deployed at a scale and speed that implant-based platforms cannot match.
Mechanism
Every BCI platform is ultimately in the business of collecting neural data and doing something with it. The device is the collection mechanism. The data is the asset. The company that accumulates the largest, most diverse dataset of human brain activity is building something that has value well beyond any individual product application.
BrainCo's deployment footprint is large — headbands used in schools across China, by elite athletes, and in clinical rehabilitation settings. That dataset is the strategic asset.
A headband deployed at scale collects the same category of data an implant does — just from many more people, much faster, with far less scrutiny.
Implication
BrainCo has drawn scrutiny for its funding connections. China Electronics Corporation — under multiple US government sanctions and listed as a Chinese military company — reportedly funded BrainCo from around 2017. Congressional committees have requested federal investigation into the company as a China-backed entity collecting brainwave data from US athletes.
The dual-use concern is not theoretical. Cognitive enhancement for military personnel and behavioral intelligence derived from large-scale neural datasets sit within the scope of what non-invasive BCI can deliver.
A device that measures brain activity at scale is a data company wearing a hardware company's branding.
Question
For companies and investors evaluating the BCI category, the strategic question is no longer whether non-invasive platforms can compete with implants — the funding and deployment data already answer that. It is whether the data asset being built, and who has access to it, has been fully priced into that evaluation.
The funding scrutiny is not a distraction from the investment thesis. It is part of the investment thesis.
The question to ask.
Where does your organization sit relative to the non-invasive BCI platform shift — as a potential user of the technology, a potential supplier to its infrastructure, or a competitor whose market it may eventually address?